Scripps Study Challenges GLP-1 Treatment Frequency Norms — Scripps Health

Event summary

Scripps Clinic study found 30 patients maintained weight loss after reducing GLP-1 treatment frequency to every 2-6 weeks.
Participants on reduced dosing showed stable or improved metabolic markers like HDL and triglycerides.
Four patients reverted to weekly dosing after initial weight regain.
Study not designed to evaluate microdosing, emphasizing adherence to FDA guidelines.

The big picture

The study challenges the current standard of indefinite weekly GLP-1 dosing, addressing patient concerns about long-term medication use and cost. This could influence treatment protocols and insurance coverage policies, potentially broadening access to weight loss medications. The findings come amid growing demand for GLP-1 drugs and supply constraints, highlighting the need for flexible treatment options.

What we're watching

Protocol Validation: Whether larger randomized trials will confirm these findings and support revised dosing guidelines.
Cost Dynamics: How reduced dosing frequency could lower out-of-pocket costs and expand patient access to GLP-1 medications.
Market Impact: The pace at which pharmaceutical companies like Eli Lilly and Novo Nordisk adapt labeling or dosing recommendations based on these results.